Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP993216priorityCriticalpatent/ECSP993216A/en
Publication of ECSP993216ApublicationCriticalpatent/ECSP993216A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Medicinal Preparation
(AREA)
Abstract
Una composición farmavcéutica, cuya composición com,prende un sensibilizador de insulina y un vehículo farmacéuticamente aceptable para el mismo, donde la composición está dispuesta para proporcionar una liberación modificada del sensibilizador de insulina, y el uso de tal composición en medicina.A pharmaceutical composition, the composition of which comprises an insulin sensitizer and a pharmaceutically acceptable carrier therefor, wherein the composition is arranged to provide a modified release of the insulin sensitizer, and the use of such composition in medicine.
ECSP9932161999-11-121999-11-12
NEW COMPOSITION AND USE II
ECSP993216A
(en)
USE OF CLORPROMAZINE AND PENTAMIDINE FOR THE MANUFACTURE OF MEDICINES, PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL PACKAGE THAT INCLUDE CHLORPROMAZINE AND PENTAMIDINE.
A PHARMACEUTICAL COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT INTENDED FOR THE TREATMENT OF A SUSCEPTIBLE VIRAL INFECTION OF TREATMENT WITH ALPHA INTERFER, A METHOD FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, FOR THE MANUFACTURE OF A MEDICINE
Pharmaceutical composition comprising: i) an at1 receptor antagonist or a salt, ii) an insulin sensitizer or a salt and iii) a pharmaceutically acceptable carrier; use for the prevention, delay of progress or treatment of hypertension, diabetes, among others (div. sol. 2034-01).
USE OF AN INSULIN SENSITIZER AND AN ANTIHIPERGLUCEMIC AGENT FOR THE PREPARATION OF A PHARMACEUTICAL MEDICINAL AND COMPOSITION THAT UNDERSTANDS SENSITIZER AND SUCH AGENT
USE OF 17 BETA-DIHYDROEKYLENINE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF 17 BETA-DIHYDROEKYLENINE-3-SULPHATE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AS ANTIOXIDANT AND PHARMACEUTICAL COMPOSITION.